{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:10:21Z","timestamp":1761822621079},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,1,6]],"date-time":"2004-01-06T00:00:00Z","timestamp":1073347200000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[2004,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of the present study was to compare the effect produced by juvenile rheumatoid arthritis (JRA) or rheumatic fever (RF) on the pharmacokinetics of acetyl salicylic acid (ASA) and its metabolites in children with autoimmune diseases (AD). <jats:italic>Methods<\/jats:italic>\u2014A prospective, open labelled study was performed in 17 children with JRA and 17 with RF who received a single dose of 25 mg ASA\/kg orally. The pharmacokinetics of ASA and its metabolites were determined. The blood and urine levels of each salicylate collected during 24 h were measured by HPLC. A group of 15 healthy teenage volunteers was included as a control group. <jats:italic>Results<\/jats:italic>\u2014The maximum plasma concentration, half\u2010life time, area under the curve and the amount of salicylates excreted were statistically different between the JRA and the RF groups, as well as between the RF group and the controls, however, there were no significant differences between the JRA group and the controls. <jats:italic>Conclusions<\/jats:italic>\u2014Dosage schemes must be adjusted for JRA patients, since the half life in these patients is longer than in RF patients. However, due to ample variability of pharmacokinetic parameters it is recommended that dose schemes are individualized on the type of autoimmune disease considered. Copyright \u00a9 2004 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/bdd.379","type":"journal-article","created":{"date-parts":[[2004,1,7]],"date-time":"2004-01-07T08:00:28Z","timestamp":1073462428000},"page":"1-7","source":"Crossref","is-referenced-by-count":15,"title":["Comparative pharmacokinetics of acetyl salicylic acid and its metabolites in children suffering from autoimmune diseases"],"prefix":"10.1002","volume":"25","author":[{"given":"Hugo","family":"Ju\u00e1rez Olgu\u00edn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janett","family":"Flores P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismael","family":"Lares Asseff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Loredo Abdal\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Carbajal Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,1,6]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"58","article-title":"Aspirin","volume":"262","author":"Weissman G","year":"1991","journal-title":"Sci Am"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000457520","article-title":"Disposition of single\u2010dose intravenous and oral aspirin in children","volume":"17","author":"Ito S","year":"1991","journal-title":"Dev Pharmacol Ther"},{"issue":"9","key":"e_1_2_1_4_2","first-page":"S57","article-title":"Relevance of the pharmacokinetics of non\u2010steroidal anti\u2010inflammatory drugs (NSAIDs) in children","volume":"11","author":"Pons G","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb03526.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/archinte.1981.00340030060012","article-title":"Adverse reactions to aspirin and related drugs","volume":"141","author":"Settipane GA","year":"1981","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.115"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600540806"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600540703"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1966.tb01926.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600570807"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.56.2.79"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/clinchem\/28.5.1200","article-title":"Improved LC of aspirin, salicylate and salicyluric acid in plasma with a modification for determining aspirin metabolites in urine","volume":"28","author":"Buskin JN","year":"1982","journal-title":"Clin Chem"},{"key":"e_1_2_1_14_2","first-page":"3","article-title":"Determination of plasma and urine levels of acetyl salicylic acid and its metabolites: gentisic acid, salicyluric acid and salicylic acid by HPLC","volume":"25","author":"Ju\u00e1rez Olgu\u00edn H","year":"1994","journal-title":"Rev Mex Cien Farm"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"Gibaldi M","year":"1982"},{"key":"e_1_2_1_16_2","first-page":"21","volume-title":"Applied Pharmacokinetics","author":"Levy G","year":"1986"},{"key":"e_1_2_1_17_2","first-page":"22","volume-title":"Estad\u00edstica Simplificada para la Investigaci\u00f3n en Ciencias de la Salud","author":"Castilla Serna L","year":"1991"},{"key":"e_1_2_1_18_2","first-page":"185","volume-title":"En Medicina Interna. Asociaci\u00f3n Mexicana","author":"Carbajal RL","year":"2000"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1972132258"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197208312870903"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198510020-00004"},{"issue":"5","key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1542\/peds.62.5S.867","article-title":"Clinical pharmacokinetics of aspirin","volume":"62","author":"Levy G","year":"1978","journal-title":"Pediatrics"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290805"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.379","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T10:55:42Z","timestamp":1700218542000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["10.1002\/bdd.379"],"URL":"https:\/\/doi.org\/10.1002\/bdd.379","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}